Reassessing Radioactive Iodine Use After Thyroidectomy in Low-Risk Differentiated Thyroid Cancer: A Systematic Review and Meta-Analysis.
Maheen Asif, Mudasar Nisar, Aliza Asif et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis evaluated the efficacy of radioactive iodine (RAI) therapy in low-risk differentiated thyroid cancer (DTC) patients post-thyroidectomy. Analyzing data from 10 studies with 5260 participants, the study found no significant differences in recurrence rates, 5-year recurrence-free survival, or treatment response between RAI and no RAI groups, with an odds ratio for recurrence of 0.66 (95% CI: 0.41-1.08; p=0.10).
Key findings
- No significant difference in recurrence rates between RAI and no RAI groups (OR 0.66, 95% CI: 0.41-1.08; p=0.10).
- 5-year recurrence-free survival rates were similar (OR 2.47, 95% CI: 0.63-9.62; p=0.19).
- Treatment response was not significantly different (excellent response: OR 1.00, 95% CI: 0.52-1.92; p=1.00).
- Secondary outcomes, including side effects, showed no significant differences.
Why it matters
The findings challenge the routine use of RAI in low-risk DTC patients, suggesting that its benefits may not justify the associated risks and costs. This could influence treatment protocols and patient management strategies.
What to keep in mind
The study highlights heterogeneity across included studies and variability in outcome definitions, which may affect the reliability of the results.